Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.
Now Viewing
EP: 1.Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)
EP: 2.Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis
EP: 3.The Role of Stem Cell Transplant in the NDMM Treatment Landscape
EP: 4.Optimal Treatment Selection for Patients with NDMM: Updates from IMS 2022
EP: 5.Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM
EP: 6.Key Considerations for Patients with Multiple Myeloma During the Treatment Journey
EP: 7.Treatment Options for MM at Early Relapse
EP: 8.Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists
Related Videos
Related Content
